---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044750"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:28:26.898896+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics appoints Gene Mack as CFO effective April 8, 2024

## Summary
- Gene Mack appointed CFO; previously CFO at Imcyse SA and OncoC4; over 25 years in life sciences.
- Annual base salary $370,000; target cash bonus of 35% of base salary.
- Inducement option to purchase 200,000 shares at $3.56, vesting over 4 years with 25% on first anniversary.
- Gianluca Fuggetta steps down as principal financial officer but remains VP of Finance and principal accounting officer.
- Mack also appointed as Secretary of the company.

## SEC filing metadata
- accession: 0001104659-24-044750
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/0001104659-24-044750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/tm2411246d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044750
- JSON: https://secwatch.observer/filing/0001104659-24-044750.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044750.txt

## Key facts
- Executive change
  Gene Mack was appointed as Chief Financial Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/0001104659-24-044750-index.htm
- Executive change
  Gianluca Fuggetta changed role as Principal Financial Officer at Gain Therapeutics, Inc..
  - Action: stepped down
  - Role: Principal Financial Officer
  source text: Upon Mr. Mack’s appointment, Gianluca Fuggetta, who had been serving as the Company’s Principal Financial Officer since March 1, 2024, will no longer serve in that capacity and will continue in his role as the Company’s Vice President of Finance and Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465924044750/0001104659-24-044750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.